Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;24(10):1061-1070.
doi: 10.2174/0115680096280761231229055929.

Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study

Yongyin Gao  1 , Hongdian Zhang  2 , Yanli Qiu  1 , Xueyan Bian  1 , Xue Wang  1 , Yue Li  1
Affiliations

Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study

Yongyin Gao et al. Curr Cancer Drug Targets. 2024.

Abstract

Background: Neoadjuvant immunotherapy, targeting the PD-1 or PD-L1, combined with chemotherapy (NICT), can improve the radical resection and survival rates for locally advanced EC. However, it may impair pulmonary function, and the effect of NICT on pulmonary function and postoperative pulmonary complications in EC patients remains unknown. This study aimed to investigate whether NICT can affect pulmonary functions and postoperative pulmonary complications in EC patients.

Methods: The study retrospectively recruited 220 EC patients who received NICT at the Department of Esophageal Cancer in Tianjin Medical University Cancer Institute & Hospital from January 2021 to June 2022. Changes in pulmonary function before and after NICT were compared. Logistic regression analysis was performed to analyze the correlations of pulmonary functions and clinical characteristics with postoperative pulmonary complications, respectively.

Results: The FEV1% pred, FVC, FVC% pred, and FEV1/FVC% significantly increased after NICT, with a P-value of 0.018, 0.005, 0.001, and 0.036, respectively. In contrast, there was a significant decline in the DLCO (8.92 ± 2.34 L before NICT vs. 7.79 ± 2.30 L after NICT; P < 0.05) and DLCO% pred (102.97 ± 26.22% before NICT vs. 90.18 ± 25.04% after NICT; P < 0.05). High DLCO and DLCO% pred at baseline levels were risk factors for DLCO reduction in EC patients after NICT. Advanced age, smoking history, FEV1% pred after NICT, and FVC% pred baseline and after therapy were risk factors for postoperative pulmonary complications, with a P-value of 0.043, 0.038, 0.048, 0.034, and 0.004, respectively. Although the DLCO level decreased after NICT, it did not increase the incidence of postoperative pulmonary complications.

Conclusion: NICT may improve pulmonary ventilation function but also lead to a decrease in DLCO and DLCO% pred in EC patients. Nevertheless, the decreased DLCO after NICT did not increase the risk of postoperative pulmonary complications.

Keywords: Esophageal cancer; NICT; acute lung injury.; pulmonary complications; pulmonary function; surgery.

PubMed Disclaimer

References

    1. He F.; Wang J.; Liu L.; Qin X.; Wan Z.; Li W.; Ping Z.; Esophageal cancer: Trends in incidence and mortality in China from 2005 to 2015. Cancer Med 2021,10(5),1839-1847 - DOI - PubMed
    1. van Hagen P.; Hulshof M.C.C.M.; van Lanschot J.J.B.; Steyerberg E.W.; Henegouwen M.I.B.; Wijnhoven B.P.L.; Richel D.J.; Nieuwenhuijzen G.A.P.; Hospers G.A.P.; Bonenkamp J.J.; Cuesta M.A.; Blaisse R.J.B.; Busch O.R.C.; ten Kate F.J.W.; Creemers G.J.; Punt C.J.A.; Plukker J.T.M.; Verheul H.M.W.; Bilgen E.J.S.; van Dekken H.; van der Sangen M.J.C.; Rozema T.; Biermann K.; Beukema J.C.; Piet A.H.M.; van Rij C.M.; Reinders J.G.; Tilanus H.W.; van der Gaast A.; Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012,366(22),2074-2084 - DOI - PubMed
    1. Chan K.K.W.; Saluja R.; Delos Santos K.; Lien K.; Shah K.; Cramarossa G.; Zhu X.; Wong R.K.S.; Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. Int J Cancer 2018,143(2),430-437 - DOI - PubMed
    1. Rittmeyer A.; Barlesi F.; Waterkamp D.; Park K.; Ciardiello F.; von Pawel J.; Gadgeel S.M.; Hida T.; Kowalski D.M.; Dols M.C.; Cortinovis D.L.; Leach J.; Polikoff J.; Barrios C.; Kabbinavar F.; Frontera O.A.; De Marinis F.; Turna H.; Lee J.S.; Ballinger M.; Kowanetz M.; He P.; Chen D.S.; Sandler A.; Gandara D.R.; Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017,389(10066),255-265 - DOI - PubMed
    1. Smyth E.C.; Gambardella V.; Cervantes A.; Fleitas T.; Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol 2021,32(5),590-599 - DOI - PubMed

MeSH terms